Navigation Links
22nd Century Group, Inc. CEO to Webcast, Live, at RetailInvestorConferences.com on December 5th
Date:12/2/2013

NEW YORK, Dec. 2, 2013 /PRNewswire/ -- 22nd Century Group, Inc. (OTCBB: XXII) today announced that Joseph Pandolfino, Chief Executive Officer, and Henry Sicignano III, President, will present at RetailInvestorConferences.com.

DATE:

December 5, 2013

TIME:   

1:15 PM EST

LINK:  

www.retailinvestorconferences.com click on the red "register / watch event now" button

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

The Retail Investor Conferences event is part of the Virtual Investor Conference Series co-hosted by MUNCmedia, Better Investing (NAIC) and PR Newswire.  Individual investors, institutional investors, financial advisors and financial analysts are invited to attend.  

It is recommended that investors pre-register to save time and receive event updates.

About 22nd Century Group:

22nd Century Group, Inc. (OTCBB: XXII) is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. 22nd Century owns or is the exclusive licensee of 114 issued patents in 78 countries plus an additional 36 pending patent applications. Goodrich Tobacco Company, LLC and Hercules Pharmaceuticals, LLC are wholly-owned subsidiaries of 22nd Century. Goodrich Tobacco is focused on commercial tobacco products and potential modified risk cigarettes. Hercules Pharmaceuticals is focused on X-22, a prescription smoking cessation aid in development. www.xxiicentury.com

About RetailInvestorConferences.com:

Since 2010, RetailInvestorConferences.com is the world's largest monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites leading-edge online conferencing by PR Newswire with the investor communications capabilities of MUNCmedia's digital public relations, content marketing and audience development services and BetterInvesting's extensive retail investor audience network.


'/>"/>
SOURCE 22nd Century Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Grace Century, FZ LLC Publishes Annual Global and Regional Financial Predications for 2014
2. KaloBios to Present at BioCenturys NewsMakers in the Biotech Industry Conference
3. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
4. MEI Pharma to Present at BioCenturys NewsMakers in the Biotech Industry Conference
5. Quorum Review’s Mitchell Parrish Presents at Embracing Change: Clinical Research in the 21st Century
6. Dalia Dergham Joins Grace Century FZ LLC International Project Team
7. Grace Century Attends Provia Laboratories Cycle II Launch
8. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
9. Eddie Leong Signs on as Advisory Board Member and Compliance Officer for Grace Century, International Research and Private Equity Consultant
10. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
11. Stanford scientists spark new interest in the century-old Edison battery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology:
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):